Please assess the completion status of the following clinical trial:

Trial Title: Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 20-40 years old~2. HBsAg, HBeAg positive and HBV DNA \>6 log10 copies/ml~3. Gestational age: 26-28 weeks with normal fetus~4. Willing to consent for the study~Exclusion Criteria:~1. Elevated ALT~2. Antiviral treatment experience patients~3. Co-infection with HAV, HCV,HDV, HIV~4. Concurrent treatment with immune modulators, cytotoxic drugs, or steroids~5. Clinical signs of threatened miscarriage in early pregnancy~6. Clinical evidence of cirrhosis and/or hepatocellular carcinoma

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Telbivudine (Type: EXPERIMENTAL): Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
- Lamivudine (Type: EXPERIMENTAL): Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
- No antiviral treatment (Type: NO_INTERVENTION): Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).